Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy

Clinical Laboratory

Volumn 57, Issue 7-8, 2011, Pages 455-467

  Chaykovska, Lyubov ^a,c   Tsuprykov, Oleg ^a,b   Hocher, Berthold ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF POTSDAM   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULE; CREATININE; FETUIN; FETUIN A; FIBROBLAST GROWTH FACTOR 23; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; PREALBUMIN; RELAXIN; SERUM ALBUMIN; TROPONIN; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIALYSIS; DYSLIPIDEMIA; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; MALNUTRITION; MORBIDITY; MORTALITY; NONHUMAN; PATHOLOGY; PREDICTION; PROTEOMICS; RENAL REPLACEMENT THERAPY; REVIEW; RISK; SEPSIS; STROKE; SUDDEN DEATH; SYSTOLIC DYSFUNCTION;

BIOLOGICAL MARKERS; BLOOD PROTEINS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; COMORBIDITY; DYSLIPIDEMIAS; FIBROBLAST GROWTH FACTORS; HOMOCYSTEINE; HUMANS; INFECTION; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALNUTRITION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEOMICS; RENAL REPLACEMENT THERAPY; TROPONIN T;

EID: 80051775077     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. de Jager D.J., et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302(16):1782-9.
2. Brunner F.P. , Seiwood N.H. Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. Kidney Int Suppl 1992;38:S4-15.
3. Hocher B., et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol 2003;14(9):2329-37. (Pubitemid 37052380)
4. Byrne C., Vemon P., Cohen J.J. Effect of age and diagnosis on survival of older patients beginning chronic dialysis. JAMA 1994;271(1):34-6. (Pubitemid 24020576)
5. Pastan S., Bailey J. Dialysis therapy. N Engl J Med 1998;338(20):1428-37.
6. Palazzuoli A., et al. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag 2010 Jun 1;6:411-8.
7. Yasue H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90(1):195-203. (Pubitemid 24203680)
8. Maisel A.S., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347(3):161-7. (Pubitemid 34764819)
9. Apple F.S., et al. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004;50(12): 2279-85. (Pubitemid 39552162)
10. Roberts M.A., et al. B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis. Clin J Am Soc Nephrol 2008;3(4):1057-65.
11. Wang A.Y., et al. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007;18(1):321-30. (Pubitemid 46053444)
12. Luchner A., et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005; 46(1):118-23. (Pubitemid 40946501)
13. DeFilippi C.R., et al. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005;46(1):35-44. (Pubitemid 40848431)
14. Mallamaci F., et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001;59(4):1559-66. (Pubitemid 32281248)
15. Zoccali C., et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12(7):1508-15. (Pubitemid 32666334)
16. Madsen L.H., et al. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007;71(6):548-54. (Pubitemid 46398682)
17. Racek J., et al. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 2006; 103(4):c162-72.
18. Paniagua R., et al. Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol 2008;3(2):407-15.
19. Satyan S., Light R.P., Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007;50(6):1009-19. (Pubitemid 350122814)
20. Gutierrez O.M., et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem 2008; 54(8):1339-48.
21. Winkler K., et al. Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 2008;29(17):2092-9.
22. Jourdain P., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49(16):1733-9. (Pubitemid 46589928)
23. Choi S.Y., et al. Association between changes in N-terminal probrain natriuretic peptide levels and changes in left ventricular mass index in stable hemodialysis patients. Nephron Clin Pract 2008;110(2):c93-100.
24. Wood G.N., et al. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. Nephrol Dial Transplant 2003;18(8): 1610-5. (Pubitemid 36939636)
25. Ammann P., et al. Raised cardiac troponins. BMJ 2004;328 (7447):1028-9. (Pubitemid 38580822)
26. Stolear J.C., et al. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. Nephrol Dial Transplant 1999;14(8):1961-7. (Pubitemid 29358895)
27. Mallamaci F., et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002;40(1):68-75. (Pubitemid 34701213)
28. Hojs R., et al. Cardiac troponin T (cTnT) in hemodialysis patients with asymptomatic and symptomatic atherosclerosis. Arch Med Res 2005;36(4):367-71. (Pubitemid 40798390)
29. deFilippi C., et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290(3):353-9.
30. Lamb E.J., Webb M.C., Abbas N.A. The significance of serum troponin T in patients with kidney disease: a review of the literature. Ann Clin Biochem 2004;41(Pt 1):1-9. (Pubitemid 38175090)
31. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45(4 Suppl 3):S1-153.
32. Wang A.Y. Biomarkers in predicting mortality and treatment in hemodialysis patients. F1000 Med Rep 2009;1:21.
33. Wang A.Y., et al. Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. Kidney Int 2006;70(3):444-52. (Pubitemid 44141570)
34. Wayand D., et al. Cardiac troponin T and I in end-stage renal failure. Clin Chem 2000;46(9):1345-50.
35. Wang A.Y., et al. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. Clin Chem 2007;53(5):882-9. (Pubitemid 46744244)
36. Wallace T.W., et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006;113(16): 1958-65.
37. Wu A.H., et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007;53(12):2086-96. (Pubitemid 350197291)
38. Kasiske B.L. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S142-56.
39. Kronenberg F., et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl;2003(84): S113-6.
40. Shurraw S. and Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006;26(5):523-39. (Pubitemid 44669427)
41. Koch M., et al. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997; 12(12):2603-11. (Pubitemid 27520682)
42. Habib A.N., et al. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2006;21(10):2881-92. (Pubitemid 44542246)
43. Liu Y., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291(4):451-9. (Pubitemid 38129749)
44. Mehrotra R. Emerging role for fetuin-A as contributor to morbidity and mortality in chronic kidney disease. Kidney Int 2007; 72(2):137-40. (Pubitemid 47067397)
45. Szweras M., et al. alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002; 277(22):19991-7. (Pubitemid 34967522)
46. Reynolds J.L., et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005;16(10):2920-30. (Pubitemid 44743490)
47. Stenvinkel P., et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 2005;67(6):2383-92. (Pubitemid 41623401)
48. Wang A.Y., et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005;20(8):1676-85. (Pubitemid 41418594)
49. Hermans M.M., et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007;72(2):202-7. (Pubitemid 47067382)
50. Ketteler M., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361(9360):827-33. (Pubitemid 36331846)
51. Shimada T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113(4):561-8. (Pubitemid 38542505)
52. Benet-Pages A., et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005;14(3):385-90. (Pubitemid 40220655)
53. Antoniucci D.M., Yamashita T., Portale A.A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006;91(8):3144-9. (Pubitemid 44271770)
54. Burnett S.M., et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21(8):1187-96.
55. Gutierrez O., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16(7):2205-15. (Pubitemid 41716454)
56. Cozzolino M., et al. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68(2):429-36. (Pubitemid 43323098)
57. Ben-Dov I.Z., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117(12):4003-8. (Pubitemid 350224109)
58. Mailliez S., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2008;74(3):389; author reply 389.
59. Gutierrez O.M., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359(6):584-92.
60. Cachofeiro V., et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008(111):S4-9.
61. Weiner D.E., et al. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int 2008;73(12):1406-12. (Pubitemid 351770495)
62. Blake G.J., Ridker P.M. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252(4):283-94. (Pubitemid 35253696)
63. Liuzzo G., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331(7):417-24. (Pubitemid 24247397)
64. Korevaar J.C., et al. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 2004;15(11):2916-22. (Pubitemid 41103401)
65. Lacson E., Jr., Levin N.W. C-reactive protein and end-stage renal disease. Semin Dial 2004;17(6):438-48. (Pubitemid 40110429)
66. Wanner C., et al., Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl, 2002(80): p. 99-102.
67. Wang, A.Y., et al. Increased circulating inflammatory proteins predict a worse prognosis with valvular calcification in end-stage renal disease: a prospective cohort study. Am J Nephrol 2008; 28(4):647-53. (Pubitemid 351832452)
68. Ducloux D., et al. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002;62(4):1417-22.
69. Zoccali C., Mallamaci F., Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant 2004;19 Suppl 5:V67-72.
70. Stenvinkel P., et al. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002: 80:103-8.
71. Ridker P.M., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101(15):1767-72. (Pubitemid 30213096)
72. Panichi V., et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004;19(5):1154-60. (Pubitemid 38628135)
73. Yudkin J.S., et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148(2):209-14.
74. Cybulsky M.I., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107(10):1255-62. (Pubitemid 32494542)
75. Dong Z.M., Brown A.A., Wagner D.D. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000;101(19):2290-5. (Pubitemid 30317132)
76. Patel S.S., et al. Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation 1998;97(1):75-81. (Pubitemid 28036157)
77. Tripepi G., Mallamaci F., Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16 Suppl 1:S83-8.
78. Stenvinkel P., et al. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000;15(10):1624-30.
79. Kendrick, J., Chonchol M.B. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008;4(12):672-81.
80. Stenvinkel P., et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3(2):505-21.
81. Honda H., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47(1):139-48. (Pubitemid 41828276)
82. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1996;7(2): 198-207.
83. Pifer T.B., et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002;62(6): 2238-45. (Pubitemid 35366181)
84. Stenvinkel P., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55(5):1899-911. (Pubitemid 29197978)
85. Ikizler T.A., et al. Spontaneous dietary protein intake during progression of chronic renal failure. J Am Soc Nephrol 1995;6(5): 1386-91.
86. Li Z.J., et al. Association between depression and malnutrition- inflammation complex syndrome in patients with continuous ambulatory peritoneal dialysis. Int Urol Nephrol 2011 Mar 2. [Epub ahead of print]
87. Herselman M., et al. Relationship between serum protein and mortality in adults on long-term hemodialysis: exhaustive review and meta-analysis. Nutrition. 2010;26(1):10-32.
88. Beddhu S., et al. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol 2004;15(3):733-42.
89. Higashi Y., et al. Low body mass index is a risk factor for impaired endothelium-dependent vasodilation in humans: role of nitric oxide and oxidative stress. J Am Coll Cardiol 2003;42(2): 256-63. (Pubitemid 36851415)
90. Foley R.N., et al. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996;7(5): 728-36. (Pubitemid 27466006)
91. Reddan D.N., et al. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003; 18(6):1167-73. (Pubitemid 36722520)
92. Kaysen G.A., et al. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001;60(1):333-40. (Pubitemid 32587572)
93. Dutton J., et al. Pre-dialysis serum albumin is a poor indicator of nutritional status in stable chronic haemodialysis patients. EDTNA ERCA J 1999;25(1):36-7.
94. Kaysen G.A. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998;9(12):2368-76. (Pubitemid 28543818)
95. Sousa M.M., et al. Evidence for the role of megalin in renal uptake of transthyretin. J Biol Chem 2000;275(49):38176-81. (Pubitemid 32009135)
96. Chertow G.M., et al. Prealbumin is as important as albumin in the nutritional assessment of hemodialysis patients. Kidney Int 2000; 58(6):2512-7.
97. Lowrie E.G., Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15(5):458-82. (Pubitemid 20174016)
98. Shah N.R., Dumler F. Hypoalbuminaemia-a marker of cardiovascular disease in patients with chronic kidney disease stages II-IV. Int J Med Sci 2008;5(6):366-70.
99. Hocher B., et al. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. Circulation 2004;109(19):2266-8. (Pubitemid 38656864)
100. Samuel C.S., et al. Relaxin-1-deficient mice develope an age-related progression of renal fibrosis. Kidney Int 2004;65(6):2054-64.
101. Samuel C.S., et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004;145(9):4125-33. (Pubitemid 39120561)
102. Hocher B., et al. Gender-dependent impact of risk factors for cardiovascular and non-cardiovascular mortality in end-stage renal disease patients on haemodialysis. Kidney Blood Press Res 2008; 31(5):360-6.
103. Hocher B., et al. Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis. J Am Soc Nephrol 2007; 18(4):1323-30. (Pubitemid 46536919)
104. Weissinger E.M., et al. Proteomics: a novel tool to unravel the patho-physiology of uraemia. Nephrol Dial Transplant 2004; 19(12):3068-77. (Pubitemid 40057630)
105. Himmelfarb J., Ikizler T.A. Hemodialysis. N Engl J Med 2010; 363(19):1833-45.
106. Giachelli C.M. The emerging role of phosphate in vascular calcification. Kidney Int 2009;75(9):890-7.
107. Filiopoulos, V., Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Inflamm Allergy Drug Targets 2009;8(5):369-82.